Business Description
![Viridian Therapeutics Inc Viridian Therapeutics Inc logo](https://static.gurufocus.com/logos/0C0000AN0B.png?14)
Viridian Therapeutics Inc
NAICS : 325199
SIC : 2834
ISIN : US60463E1038
Description
Viridian Therapeutics Inc is a clinical-stage biopharmaceutical company that engages in developing multiple product candidates to treat patients who suffer from thyroid eye disease. Its product candidate VRDN-001 is an insulin-like growth factor-1 receptor (IGF-1R) monoclonal antibody (mAb) being developed for the potential treatment for patients with thyroid eye disease.
Financial Strength
7/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Cash-To-Debt | 29.12 | |||||
Equity-to-Asset | 0.92 | |||||
Debt-to-Equity | 0.04 | |||||
Debt-to-EBITDA | -0.1 | |||||
Piotroski F-Score | 3/9 | |||||
Altman Z-Score | 10.05 | |||||
Beneish M-Score | -2.18 | |||||
WACC vs ROIC |
Growth Rank
6/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | -71.3 | |||||
3-Year EBITDA Growth Rate | 44.6 | |||||
3-Year EPS without NRI Growth Rate | 22.7 | |||||
3-Year FCF Growth Rate | 21 | |||||
Future 3-5Y EPS without NRI Growth Rate | 16.46 | |||||
Future 3-5Y Total Revenue Growth Rate | 442.09 |
Momentum Rank
1/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
5-Day RSI | 85.37 | |||||
9-Day RSI | 70.73 | |||||
14-Day RSI | 61.99 | |||||
6-1 Month Momentum % | -41.18 | |||||
12-1 Month Momentum % | -35.83 |
Liquidity Ratio
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Current Ratio | 23.99 | |||||
Quick Ratio | 23.99 | |||||
Cash Ratio | 23.47 |
Dividend & Buy Back
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -133.7 | |||||
Shareholder Yield % | -21.14 |
Profitability Rank
1/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Operating Margin % | -82595.14 | |||||
Net Margin % | -75737.85 | |||||
FCF Margin % | -58656.6 | |||||
ROE % | -55.23 | |||||
ROA % | -49.85 | |||||
ROIC % | -1923.71 | |||||
ROC (Joel Greenblatt) % | -6343.11 | |||||
ROCE % | -52.56 |
GF Value Rank
1/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
PS Ratio | 2448.33 | |||||
PB Ratio | 2.45 | |||||
Price-to-Tangible-Book | 2.45 | |||||
EV-to-EBIT | -2.53 | |||||
EV-to-Forward-EBIT | -3.53 | |||||
EV-to-EBITDA | -2.53 | |||||
EV-to-Forward-EBITDA | -3.54 | |||||
EV-to-Revenue | 1892.83 | |||||
EV-to-Forward-Revenue | 1835.47 | |||||
EV-to-FCF | -3.24 | |||||
Price-to-Median-PS-Value | 244.83 | |||||
Price-to-Net-Current-Asset-Value | 2.47 | |||||
Price-to-Net-Cash | 1.66 | |||||
Earnings Yield (Greenblatt) % | -39.53 | |||||
FCF Yield % | -17.94 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Viridian Therapeutics Inc Executives
DetailsAnalyst Estimate
Key Statistics
Name | Value | ||
---|---|---|---|
Revenue (TTM) (Mil €) | 0.265 | ||
EPS (TTM) (€) | -4.158 | ||
Beta | 0.64 | ||
Volatility % | 61.65 | ||
14-Day RSI | 61.99 | ||
14-Day ATR (€) | 0.306585 | ||
20-Day SMA (€) | 11.445 | ||
12-1 Month Momentum % | -35.83 | ||
52-Week Range (€) | 10.2 - 21.4 | ||
Shares Outstanding (Mil) | 63.82 |
Piotroski F-Score Details
Year:
Component | Result | ||
---|---|---|---|
Piotroski F-Score | 3 | ||
Positive ROA | |||
Positive CFROA | |||
Higher ROA yoy | |||
CFROA > ROA | |||
Lower Leverage yoy | |||
Higher Current Ratio yoy | |||
Less Shares Outstanding yoy | |||
Higher Gross Margin yoy | |||
Higher Asset Turnover yoy |
Viridian Therapeutics Inc Filings
Filing Date | Document Date | Form | ||
---|---|---|---|---|
No Filing Data |
Viridian Therapeutics Inc Stock Events
Event | Date | Price(€) | ||
---|---|---|---|---|
No Event Data |
Viridian Therapeutics Inc Frequently Asked Questions
What is Viridian Therapeutics Inc(FRA:1S1)'s stock price today?
The current price of FRA:1S1 is €12.50. The 52 week high of FRA:1S1 is €21.40 and 52 week low is €10.20.
When is next earnings date of Viridian Therapeutics Inc(FRA:1S1)?
The next earnings date of Viridian Therapeutics Inc(FRA:1S1) is 2024-08-08 Est..
Does Viridian Therapeutics Inc(FRA:1S1) pay dividends? If so, how much?
Viridian Therapeutics Inc(FRA:1S1) does not pay dividend.
Press Release
Subject | Date | |||
---|---|---|---|---|
No Press Release |